GCP
INZY

GSA Capital Partners’s Inozyme Pharma INZY Stock Holding History

GSA Capital Partners’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-89,651
Closed -$82K – 1933
2025
Q1 		$82K Buy
+89,651
New +$124K 0.01% 1521
2024
Q4 		– Sell
-35,402
Closed -$185K – 1802
2024
Q3 		$185K Sell
35,402
-5,529
-14% -$28.7K 0.01% 1427
2024
Q2 		$183K Sell
40,931
-90,167
-69% -$437K 0.01% 1470
2024
Q1 		$1M Sell
131,098
-35,906
-22% -$197K 0.08% 432
2023
Q4 		$711K Buy
167,004
+74,358
+80% +$264K 0.06% 581
2023
Q3 		$389K Buy
92,646
+65,842
+246% +$335K 0.03% 944
2023
Q2 		$149K Buy
+26,804
New +$158K 0.01% 1339

Other funds holding INZY

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

GSA Capital Partners's INZY Position: Q2 2025 in Review

GSA Capital Partners sold out of Inozyme Pharma (INZY) in Q2 2025, closing a stake of 89,651 shares — an estimated $82K sold.

GSA Capital Partners first reported a position in INZY in Q2 2023 and held it in 7 quarters. The position peaked at $1M in Q1 2024. 86 funds tracked by Wall St. Rank hold INZY as of Q2 2025.

  • GSA Capital Partners reported no remaining Inozyme Pharma position as of Q2 2025 after selling out during the quarter.
  • GSA Capital Partners sold 89,651 Inozyme Pharma shares in Q2 2025, an estimated $82K.
  • GSA Capital Partners first reported a position in Inozyme Pharma in Q2 2023 and held it in 7 quarters.
  • GSA Capital Partners's Inozyme Pharma position peaked at $1M in Q1 2024.
  • 86 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2025.

Based on GSA Capital Partners's 13F filing for Q2 2025, filed 22 Jul 2025.